RA
KYMR icon

Royce & Associates’s Kymera Therapeutics KYMR Stock Holding History

Royce & Associates’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,797
Closed -$1.47M – 810
2025
Q2 		$1.47M Buy
+33,797
New +$1.16M 0.02% 636
2024
Q2 		– Sell
-7,076
Closed -$284K – 897
2024
Q1 		$284K Sell
7,076
-8,928
-56% -$319K ﹤0.01% 819
2023
Q4 		$407K Buy
+16,004
New +$286K ﹤0.01% 802

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Royce & Associates's KYMR Position: Q3 2025 in Review

Royce & Associates sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 33,797 shares — an estimated $1.47M sold.

Royce & Associates first reported a position in KYMR in Q4 2023 and held it in 3 quarters. The position peaked at $1.47M in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Royce & Associates reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Royce & Associates sold 33,797 Kymera Therapeutics shares in Q3 2025, an estimated $1.47M.
  • Royce & Associates first reported a position in Kymera Therapeutics in Q4 2023 and held it in 3 quarters.
  • Royce & Associates's Kymera Therapeutics position peaked at $1.47M in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Royce & Associates's 13F filing for Q3 2025, filed 12 Nov 2025.